Methuselah Foundation congratulates Organovo and the tissue engineering community for the breakthrough release of the first commercially available 3D bio-printer, heralding the promising future of regenerative medicine. As noted in the February 18 edition of The Economist, “The ability to make organs as they are needed would not only relieve suffering but also save lives. And that possibility may be closer with the arrival of the first commercial 3D bio-printer for manufacturing human tissue and organs.”
Methuselah Foundation also acknowledges the important contribution of its donors to the future of generative medicine. Through their generosity and foresight, the Foundation became one of the founding investors in Organovo.
Gabor Forgacs of the University of Missouri is the Chief Scientific Officer and a Organovo founder, he developed the prototype on which the new 3D bio-printer is based. In addition to using the printer to further their own development of replacement human tissue, Organovo will supply the units to tissue engineering research centers of excellence who are investigating human tissue repair and organ replacement.
Dave Gobel, CEO of the Foundation said “Methuselah Foundation is delighted and gratified at Organovo's breathtaking progress and promise. We strongly believe in the vast potential represented by tissue engineering and believe the visionaries at Organovo such as Dr. Forgacs are uniquely qualified to lead the way. Ultimately it is these donors who vote with their time and money to move Methuselah Foundation decisively forward toward realization of its mission.”
